var data={"title":"Valproate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valproate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7137?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">see &quot;Valproate: Drug information&quot;</a> and <a href=\"topic.htm?path=valproate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valproate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708868\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first 6 months of treatment. Serious or fatal hepatotoxicity may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Monitor patients closely for appearance of these symptoms. Perform serum liver tests prior to therapy and at frequent intervals thereafter, especially during the first 6 months.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Children younger than 2 years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When these products are used in this patient group, use with extreme caution and as a sole agent. Weigh the benefits of therapy against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Patients with mitochondrial disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome). Valproate is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children younger than 2 years who are clinically suspected of having a mitochondrial disorder. In patients older than 2 years who are clinically suspected of having a hereditary mitochondrial disease, only use after other anticonvulsants have failed. Closely monitor this older group of patients during treatment for the development of acute liver injury with regular clinical assessments and serum liver testing. Perform POLG mutation screening in accordance with current clinical practice.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Valproate can cause major congenital malformations, particularly neural tube defects (eg, spina bifida). In addition, valproate can cause decreased IQ scores following in utero exposure. Only use valproate to treat pregnant women with epilepsy if other medications have failed to control their symptoms or are otherwise unacceptable. Do not administer valproate to a woman of childbearing potential unless the drug is essential to the management of her medical condition. This is especially important when valproate use is considered for a treatment of a spontaneously reversible condition not ordinarily associated with permanent injury or risk of death (eg, migraine). Women should use effective contraception while using valproate.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">An information sheet describing the teratogenic potential of valproate is available for patients.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pancreatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, ordinarily discontinue valproate. Initiate alternative treatment for the underlying medical condition as clinically indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233020\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Depacon;</li>\n      <li>Depakene;</li>\n      <li>Depakote;</li>\n      <li>Depakote ER;</li>\n      <li>Depakote Sprinkles;</li>\n      <li>Stavzor [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233021\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Divalproex;</li>\n      <li>Apo-Valproic;</li>\n      <li>Depakene;</li>\n      <li>Dom-Divalproex;</li>\n      <li>Dom-Valproic Acid;</li>\n      <li>Dom-Valproic Acid E.C.;</li>\n      <li>Epival;</li>\n      <li>Mylan-Divalproex;</li>\n      <li>Mylan-Valproic;</li>\n      <li>Novo-Valproic;</li>\n      <li>PHL-Valproic Acid;</li>\n      <li>PHL-Valproic Acid E.C.;</li>\n      <li>PMS-Divalproex;</li>\n      <li>PMS-Valproic Acid;</li>\n      <li>PMS-Valproic Acid E.C.;</li>\n      <li>ratio-Valproic;</li>\n      <li>Sandoz-Valproic;</li>\n      <li>Teva Divalproex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055961\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Infantile Spasms, Treatment</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445214\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity, valproic acid and derivatives are not preferred agents for use in neonates. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Refractory seizures:</b> Limited data available: Oral: Loading dose: 20 mg/kg, followed by a maintenance dose of 5 to 10 mg/kg/dose every 12 hours; adjust dose according to serum concentrations; dosing based on a report of six neonates (GA: 30 to 41 weeks) that showed oral valproic acid effectively controlled seizure activity in five of six patients; however, therapy was discontinued in 50% of the patients due to hyperammonemia; frequent monitoring is recommended (Evans 1998; Gal 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Refractory status epilepticus:</b> Limited data available: IV: Loading dose: 20 to 40 mg/kg followed by a continuous IV infusion of 5 mg/kg/<b>hour</b> was used in five neonates; once patients were seizure-free for 12 hours and no longer had seizure activity on EEG, the infusion rate was decreased every 2 hours by 1 mg/kg/<b>hour</b> (Uberall 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055952\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">see &quot;Valproate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Use of Depakote-ER in pediatric patients &lt;10 years of age is not recommended; do not confuse Depakote-ER with Depakote. <b>Erroneous substitution of Depakote (delayed release tablets) for Depakote-ER has resulted in toxicities; only Depakote-ER is intended for once daily administration. Note:</b> Stavzor has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine prophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Divalproex sodium (eg, Depakote tablets):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;7 years and Adolescents &le;16 years: Limited data available: Oral: Initial 10 to 15 mg/kg/day in 2 divided doses; maximum initial dose: 250 mg/dose. Titrate as needed over 4 to 6 weeks to 40 to 45 mg/kg/day in 2 divided doses; maximum daily dose: 1,000 mg/<b>day</b> (AAN [Lewis 2004]; Caruso 2000; Gunner 2008). Dosing based on an open-label trial of divalproate sodium (n=42; age range: 7 to 16 years); dose was initiated at 15 mg/kg/day in 2 divided doses and increased as needed over 6 weeks to 45 mg/kg/day in 2 divided doses. After 4 months, 78.5% of subjects had a 50% decrease in headaches frequency, 14.2% had a 75% decrease in headache frequency, and 9.5% became headache free (Caruso 2000). Other trials have also shown efficacy with similar daily dose range (500 to 1,000 mg/day): In a comparative trial with propranolol results showed both treatments reduced headache duration, severity, and frequency (ie, &ge;50% reduction; divalproex sodium: 72%, propranolol: 69%) (Ashrafi 2005), and a small (n=10) open-label trial of pediatric patients 9 to 17 years showed a statistically significant decrease in mean frequency of headache attacks, severity, and duration with divalproex sodium therapy (Serdaroglu 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;17 years: Depakote: Oral: 250 mg twice daily; adjust dose based on patient response; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stavzor: Children &ge;12 years and Adolescents: Oral: 250 mg twice daily; adjust dose based on patient response; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Depakote ER: Limited data available: Children &ge;12 years and Adolescents: Oral: 500 mg once daily for 15 days, may increase to 1,000 mg once daily; adjust dose based on patient response; usual dosage range: 250 to 1,000 mg/day; dose should be individualized; if smaller dosage adjustments are needed, use Depakote delayed release tablets; results from a Phase 3, long-term (12 months) open-label trial of 241 patients (age: 12 to 17 years) showed a 75% decrease in median 4-week headache days between the first and fourth months of the trial (Apostol 2009). In a short-term (12 weeks), double-blind, randomized placebo-controlled trial of 304 patients (age: 12 to 17 years), Depakote ER (250 to 1,000 mg/day) was no different than placebo at reducing the 4 week headache rate; however, a large placebo effect was observed in the study population (Apostol 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures disorders:</b> <b>Note:</b> Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity in patients &lt;2 years, valproic acid and derivatives are not preferred agents in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>General dosing (including complex partial seizures, mixed seizure disorders, tonic-clonic):</i> Children and Adolescents: Limited data available for some seizure types and ages &lt;10 years (Pi&ntilde;a-Garza 2013): Initial: 10 to 15 mg/kg/day in 1 to 3 divided doses; increase by 5 to 10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30 to 60 mg/kg/day in 2 to 3 divided doses; Depakote and Depakote Sprinkle can be given twice daily; <b>Note:</b> Children receiving more than 1 anticonvulsant (ie, polytherapy) may require doses up to 100 mg/kg/day in 3 to 4 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Absence seizures, simple and complex:</i> Children and Adolescents: Initial: 15 mg/kg/day in 1 to 3 divided doses; increase by 5 to 10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30 to 60 mg/kg/day in 2 to 3 divided doses; Depakote and Depakote Sprinkle can be given twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion to Depakote ER from a stable dose of Depakote:</i> May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion to monotherapy from adjunctive therapy:</i> The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when valproate or derivative therapy is initiated or 1 to 2 weeks following valproate or derivative initiation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral: Children and Adolescents: Limited data available in some cases depending on seizure types and age (Pi&ntilde;a-Garza 2013): IV: Total daily IV dose is equivalent to the total daily oral dose; however, IV dose should be divided with a frequency of every 6 hours; if IV form is administered 2 to 3 times/day, close monitoring of trough concentrations is recommended; switch patients to oral product as soon as clinically possible as IV use &gt;14 days has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Limited data available: Children and Adolescents: Dilute oral syrup 1:1 with water for use as a retention enema (Graves 1987):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 17 to 20 mg/kg once</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 10 to 15 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus; refractory:</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: Initial: 20 to 40 mg/kg; some experts recommend an additional 20 mg/kg after 10 to 15 minutes if needed (Brophy 2012); there is limited experience with loading doses &gt;40 mg/kg in infants.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">In one retrospective study, an initial loading dose of 25 mg/kg was effective in stopping seizure activity within 20 minutes after the end of the infusion in all 18 patients treated for status epilepticus (Yu 2003). A separate retrospective trial found a higher efficacy rate in pediatric patients who received an initial loading dose of 30 to 40 mg/kg (73.3%, n=15) compared to 20 to 30 mg/kg (46.2%, n=26) or &gt;40 mg/kg (40%, n=10) (Uberall 2000). In an open-label, randomized comparative trial, an initial loading dose of 30 mg/kg was administered (n=20; age range: 7 months to 10 years of age; mean age: 3 years); a repeat bolus of 10 mg/kg could be administered if seizures were not controlled within 10 minutes; mean required dose: 37.5 &plusmn; 4.4 mg/kg; median required dose: 40 mg/kg (Mehta 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: IV infusion: 5 mg/kg/<b>hour</b> after the loading dose was used in pediatric continuous IV infusion studies (Mehta 2007; Uberall 2000); once patients were seizure-free for 6 hours, the infusion rate was decreased by 1 mg/kg/<b>hour</b> every 2 hours (Mehta 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Dilute oral syrup 1:1 with water for use as a retention enema (Snead 1985):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 15 to 20 mg/kg once</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: 10 to 15 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures: Note:</b> Administer doses &gt;250 mg/day in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Simple and complex absence seizure: Initial: 15 mg/kg/day; increase by 5 to 10 mg/kg/day at weekly intervals until therapeutic concentrations are achieved; maximum daily dose: 60 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complex partial seizure: Initial: 10 to 15 mg/kg/day; increase by 5 to 10 mg/kg/day at weekly intervals until therapeutic concentrations are achieved; maximum daily dose: 60 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Regular release and delayed release formulations are usually given in 2 to 4 divided doses per day; extended release formulation (Depakote ER) is usually given once daily. In patients previously maintained on regular release valproic acid therapy (Depakene) who convert to delayed release divalproex sodium tablets (Depakote) or valproic acid capsules (Stavzor), the same daily dose and frequency as the regular release should be used; once therapy is stabilized, the frequency of Depakote or Stavzor may be adjusted to 2 to 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion to Depakote ER from a stable dose of Depakote: May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion to monotherapy from adjunctive therapy: The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when the valproic acid or derivative is initiated or 1 to 2 weeks following valproic acid or derivative initiation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Total daily IV dose should be equivalent to the total daily dose of the oral valproic acid or derivative; administer dose with the same frequency as oral products; switch patient to oral products as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mania: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Depakote tablet, Stavzor: Initial: 750 mg/day in divided doses; adjust dose as rapidly as possible to desired clinical effect; maximum daily dose: 60 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Depakote ER: Initial: 25 mg/kg/day given once daily; adjust dose as rapidly as possible to desired clinical effect; maximum daily dose: 60 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Depakote tablet, Stavzor: Initial: 250 mg twice daily; adjust dose based on patient response, maximum daily dose: 1,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Depakote ER: Initial: 500 mg once daily for 7 days, may increase to 1,000 mg once daily; adjust dose based on patient response; usual dosage range 500 to 1,000 mg/day; dose should be individualized; if smaller dosage adjustments are needed, use Depakote delayed release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: Mild to severe impairment: No dosage adjustment required (including patients on hemodialysis); however, protein binding is reduced in patients with renal impairment; monitoring <b>only</b> total valproate serum concentrations may be misleading.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: Not recommended for use in hepatic disease; clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction of valproate. Free concentrations of valproate may be elevated while total concentrations appear normal; therefore, monitoring <b>only</b> total valproate concentrations may be misleading.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232991\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as valproic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stavzor: 125 mg [DSC], 250 mg [DSC], 500 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release Sprinkle, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote Sprinkles: 125 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as valproate sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depacon: 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as valproate sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as valproate sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene: 250 mg/5 mL (480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (5 mL, 10 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 125 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 250 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote: 500 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as divalproex sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote ER: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232975\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22782778\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">see &quot;Valproate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strengths of divalproex sodium and valproate sodium products are expressed in terms of valproic acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49367104\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Stavzor has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16335927\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakene, Depakote, Depakote ER: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060,019680s047lbl.pdf#page=97&amp;token=gUxbz1UN2BSgaiRLjpoLwmokJIz/EbBX7qsoVvB4wjSI7DzGpZXpmEyGrk6NX6NvxB36wK0jmMnTTiMX1OcwgqQ1MUTjeHgzXPOpQFS1ZrZF8dNGl8JWKEFrG3LXbPKR&amp;TOPIC_ID=12873\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018723s060,019680s047lbl.pdf#page=97</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stavzor: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WjFwRaG4FaLSZzydQSVIIFw==&amp;TOPIC_ID=12873\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055966\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May administer with food to decrease adverse GI effects; do not administer with carbonated drinks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote ER: Swallow whole; do not crush or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote sprinkle capsules: May be swallowed whole or capsule may be opened and sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce) to be used immediately; do not crush or chew sprinkle beads; do not store drug food mixture for later use.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene capsule, Stavzor: Swallow whole; do not break, crush, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer recommendations: Dilute dose prior to administration; infuse over 60 minutes; maximum infusion rate: 20 mg/minute; <b>Note:</b> Rapid infusions may be associated with an increase in adverse effects; infusions of &le;15 mg/kg administered over 5 to 10 minutes (1.5 to 3 mg/kg/minute) were generally well tolerated (Ramsay, 2003). In pediatric patients, an infusion rate of 1.5 to 3 mg/kg/minute has been recommended (Brophy 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rapid IV loading doses:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children: Dilute dose prior to administration; administer at 1.5 to 3 mg/kg/minute (Brophy 2012; Yu 2003). Faster infusion rates have been used in some studies; doses of 20 to 40 mg/kg have been administered over 1 to 5 minutes (Meht, 2007; Uberall 2000). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: The European Federation of Neurological Societies (EFNS) recommends maximum administration rates of 6 mg/kg/minute (Meierkord 2006). <b>Note:</b> In two adult studies, the drug was administered undiluted at rates as high as 10 mg/kg/minute (Limdi 2007) and 500 mg/minute (Limdi 2005). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rectal: Dilute oral solution or syrup prior to rectal administration (Graves 1987) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133423\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233013\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakene: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stavzor: Store at 25&deg;C (77&deg; F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral sprinkle capsules (Depakote): Store below 25&deg;C (77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution (Depakene): Store below 30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakote: Store below 30&deg;C (86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depakote ER: Store tablets at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epival [Canadian product]: Store at 15&deg;C and 25&deg;C (59&deg;F and 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Store at controlled room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Stable in D<sub>5</sub>W, NS, and LR for at least 24 hours when stored in glass or PVC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055965\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release capsules and syrup (Depakene): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults), monotherapy and adjunctive therapy of simple and complex absence seizures (FDA approved in pediatric patients [age not specified] and adults), and adjunctive therapy in patients with multiple seizure types that include absence seizures (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms; oral syrup has also been used rectally for treatment of seizure disorders when oral route is not available </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delayed release capsules (Stavzor): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures (FDA approved pediatric patients [age not specified] and adults); prophylaxis of migraine headaches (FDA approved in ages &ge;12 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delayed release tablets (Depakote): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures [FDA approved in pediatric patients (age not specified) and adults]; prophylaxis of migraine headaches (FDA approved in ages &ge;17 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablets (Depakote ER): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures; monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures (all epilepsy types listed: FDA approved in ages &ge;10 years and adults); prophylaxis of migraine headaches (FDA approved in adults); treatment of manic episodes of bipolar disorders (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sprinkle capsules (Depakote): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); monotherapy and adjunctive therapy of simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Injection (Depacon): Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures (FDA approved in ages &ge;10 years and adults); monotherapy and adjunctive therapy of simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms. <b>Note:</b> Parenteral formulation is indicated for patients in whom oral administration of valproic acid or derivatives is temporarily not feasible; has also been used in patients with absence status epileptics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233076\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakene may be confused with Depakote </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote may be confused with Depakene, Depakote ER, Senokot</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Depakote ER may be confused with divalproex enteric coated</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valproate sodium may be confused with vecuronium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233074\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with oral administration, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, facial edema, hypertension, hypotension, orthostatic hypotension, palpitations, peripheral edema, tachycardia, vasodilatation (more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormal gait, abnormality in thinking, agitation, amnesia, anxiety, ataxia, catatonia, chills, confusion, depression, dizziness (more common in oral), drowsiness (more common in oral), emotional lability, hallucination, headache (more common in oral), hyper-reflexia, hypertonia, insomnia, malaise, myasthenia, nervousness (more common in oral), pain (more common in oral), paresthesia, personality disorder, sleep disorder, speech disturbance, tardive dyskinesia, twitching, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, erythema nodosum, furunculosis, maculopapular rash, pruritus, seborrhea, skin rash, vesiculobullous dermatitis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, menstrual disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in oral), anorexia, constipation, diarrhea (more common in oral), dysgeusia, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, gastroenteritis, gingival hemorrhage, glossitis, hematemesis, hiccups, increased appetite, nausea (more common in oral), oral mucosa ulcer, pancreatitis, periodontal abscess, stomatitis, vomiting (more common in oral), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Cystitis, dysmenorrhea, dysuria, urinary frequency, urinary incontinence, vaginal hemorrhage, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Ecchymoses, hypoproteinemia, petechia, prolonged bleeding time, thrombocytopenia (dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection, infection, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, discoid lupus erythematosus, dysarthria, hypokinesia, leg cramps, myalgia, neck pain, neck stiffness, osteoarthritis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, diplopia, dry eye syndrome, eye pain, nystagmus, photophobia, visual disturbance (amblyopia, blurred vision)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness, otitis media, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, epistaxis, flu-like symptoms, pharyngitis (more common in oral), pneumonia, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal behavior, abnormal thyroid function tests, acute porphyria, aggressive behavior, agranulocytosis, anaphylaxis, anemia, aplastic anemia, asthenospermia, azoospermia, bone fracture, bone marrow depression, bradycardia, brain disease (rare), breast hypertrophy, cerebral atrophy (reversible or irreversible), change in prothrombin time, changes of hair (color, texture), coma (rare), decreased bone mineral density, decreased plasma carnitine concentrations, decreased platelet aggregation, decreased spermatozoa motility, dementia, developmental delay (learning disorder), disturbance in attention, DRESS syndrome, drug-induced Parkinson disease, emotional disturbance, eosinophilia, erythema multiforme, euphoria, Fanconi-like syndrome (rare, in children), galactorrhea, hemorrhage, hepatic failure, hepatotoxicity, hirsutism, hostility, hyperactivity, hyperammonemia, hyperammonemic encephalopathy (in patients with UCD), hyperandrogenism, hyperglycinemia, hypersensitivity angiitis, hypersensitivity reaction, hypoesthesia, hypofibrinogenemia, hyponatremia, hypothermia, increased testosterone level, injection site inflammation, leukopenia, lymphocytosis, macrocytosis, male infertility, myelodysplasia, nail bed changes, nail disease, oligospermia, ostealgia, osteopenia, osteoporosis, pancytopenia, parotid gland enlargement, polycystic ovary syndrome (rare), psychomotor disturbance, psychosis, seizure (paradoxical), severe hypersensitivity (with multiorgan dysfunction), SIADH, skin photosensitivity, sleep disorder, spermatozoa disorder (abnormal morphology), Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, toxic epidermal necrolysis (rare), urinary incontinence, urinary tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232998\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to valproic acid, divalproex, derivatives, or any component of the formulation; hepatic disease or significant impairment; urea cycle disorders; pregnant women for the prevention of migraine; known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg, Alpers-Huttenlocher syndrome [AHS]) or children &lt;2 years of age suspected of having a POLG-related disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Known porphyria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232979\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood disorders: May cause dose-related thrombocytopenia, inhibition of platelet aggregation, and bleeding. In some cases, platelet counts may be normalized with continued treatment; however, reduce dose or discontinue drug if patient develops evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation. Evaluate platelet counts prior to initiating therapy and periodically thereafter. Probability of thrombocytopenia increases with total valproate levels &ge;110 mcg/mL in females or &ge;135 mcg/mL in males. In addition to platelets, valproate may be associated with a decrease in other cell lines and myelodysplasia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Brain atrophy: Reversible and irreversible cerebral and cerebellar atrophy have been reported; motor and cognitive function should be routinely monitored to assess for signs and symptoms of brain atrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: <b>[US Boxed Warning]: Hepatic failure resulting in fatalities has occurred in patients, usually in the initial 6 months of therapy; children &lt;2 years of age are at considerable risk. Risk is also increased in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome [AHS]). </b> Other risk factors include organic brain disease, mental retardation with severe seizure disorders, congenital metabolic disorders, and patients on multiple anticonvulsants. Monitor patients closely for appearance of malaise, weakness, facial edema, anorexia, jaundice, and vomiting; discontinue immediately with signs/symptom of significant or suspected impairment. Liver function tests should be performed at baseline and at regular intervals after initiation of therapy, especially within the first 6 months. Hepatic dysfunction may progress despite discontinuing treatment. Should only be used as monotherapy and with extreme caution in children &lt;2 years of age and/or patients at high risk for hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperammonemia/encephalopathy: Hyperammonemia and/or encephalopathy, sometimes fatal, has been reported following the initiation of valproate therapy and may be present with normal transaminase levels. Ammonia levels should be measured in patients who develop unexplained lethargy and vomiting, or changes in mental status or in patients who present with hypothermia. Discontinue therapy if ammonia levels are increased and evaluate for possible urea cycle disorder (UCD). Hyperammonemic encephalopathy has been reported in patients with UCD, particularly ornithine transcarbamylase deficiency. Use is contraindicated in patients with known UCD. Evaluation of UCD should be considered for the following patients prior to the start of therapy: History of unexplained encephalopathy or coma; encephalopathy associated with protein load; pregnancy or postpartum encephalopathy; unexplained mental retardation; history of elevated plasma ammonia or glutamine; history of cyclical vomiting and lethargy; episodic extreme irritability, ataxia; low BUN or protein avoidance; family history of UCD or unexplained infant deaths (particularly male); or signs or symptoms of UCD (hyperammonemia, encephalopathy, respiratory alkalosis). Hyperammonemia and/or encephalopathy may also occur with concomitant topiramate therapy in patients who previously tolerated monotherapy with either medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothermia: Hypothermia (unintentional drop in core body temperature to &lt;35&deg;C/95&deg;F) has been reported with valproate therapy; hypothermia may or may not be associated with hyperammonemia; may also occur with concomitant topiramate therapy following topiramate initiation or dosage increase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity reactions (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious, sometimes fatal multiorgan hypersensitivity reactions have rarely been reported with some antiepileptic drugs including valproate therapy in adults and children; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: <b>[US Boxed Warning]: Cases of life-threatening pancreatitis, occurring at the start of therapy or following years of use, have been reported in adults and children.</b> Some cases have been hemorrhagic with rapid progression of initial symptoms to death. Promptly evaluate symptoms of abdominal pain, nausea, vomiting, and/or anorexia; should generally be discontinued if pancreatitis is diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute head trauma: Not recommended for post-traumatic seizure prophylaxis in patients with acute head trauma; study results for this indication suggested increased mortality with IV valproate use compared to IV phenytoin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Contraindicated with significant impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mitochondrial disease: <b>[US Boxed Warning]: Risk of valproate-induced acute liver failure and death is increased in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial polymerase gamma (POLG) gene (eg, Alpers Huttenlocher syndrome [AHS]). Use is contraindicated in patients with known mitochondrial disorders caused by POLG mutations and children &lt;2 years of age suspected of having a POLG-related disorder. Use in children &ge;2 years of age suspected of having a POLG-related disorder only after other anticonvulsants have failed and with close monitoring for the development of acute liver injury.</b> POLG mutation testing should be performed in accordance with current clinical practice.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution as elderly patients may be more sensitive to sedating effects and dehydration; in some elderly patients with somnolence, concomitant decreases in nutritional intake and weight loss were observed. Reduce initial dosages in elderly and closely monitor fluid status, nutritional intake, somnolence, and other adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children &lt;2 years of age are at increased risk for fatal hepatotoxicity; if valproate therapy is used in this age group, use with extreme caution and only as monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: May cause major congenital malformations such as neural tube defects (eg, spina bifida) and decreased IQ scores following in utero exposure. Use is contraindicated in pregnant women for the prevention of migraine. Use is not recommended in women of childbearing potential for any other condition unless valproate is essential to manage her condition and alternative therapies are not appropriate. Effective contraception should be used during therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal: Medication residue in stool has been reported (rarely) with oral Depakote (divalproex sodium) formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy). In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Viral replication: <i>In vitro</i> studies have suggested valproate stimulates the replication of HIV and CMV viruses under experimental conditions. The clinical consequence of this is unknown, but should be considered when monitoring affected patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819284\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neonates, infants, and children &lt;2 years of age are at considerably increased risk for hepatotoxicity/hepatic failure, especially those on anticonvulsant polytherapy, with congenital metabolic disorders, with severe seizure disorders and mental retardation, or with organic brain disease; monitor patients closely for appearance of malaise, loss of seizure control, weakness, facial edema, anorexia, jaundice, and vomiting; monitor liver enzymes prior to therapy and at frequent intervals, especially during the first 6 months; discontinue valproic acid and derivatives if hepatotoxicity occurs; hepatic dysfunction may progress despite discontinuing treatment. Although carnitine is clearly indicated for the management of valproic acid overdose and hepatotoxicity (and strongly recommended for select patients at high risk of valproic acid-associated hepatotoxicity), the role of routine prophylactic carnitine supplementation is unclear (Freeman, 1994; Raskind, 2000). A case of a fatal hepatotoxic reaction has been reported in a child receiving valproic acid despite carnitine supplementation (Murphy, 1993). A valproic acid-associated Reye's-like syndrome has also been reported (Hilmas, 2000). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Rare multiorgan hypersensitivity reactions have been reported pediatric patients in association with initiation of valproic acid and derivatives; at least one death has been reported; patient may present with fever and rash in association with symptoms of organ system dysfunction [eg, lymphadenopathy, hepatitis, abnormalities in liver function tests, hematologic abnormalities (eosinophilia, neutropenia, thrombocytopenia), pruritus, oliguria, nephritis, arthralgia, asthenia]; valproic acid and derivatives should be discontinued in patients suspected of having multiorgan hypersensitivity reactions. Medication residue in stool has been reported (rarely) with oral Depakote (divalproex sodium) formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy). In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233062\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak); <b>Induces</b> CYP2A6 (weak/moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15578418\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12873&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amdinocillin: Valproate Products may enhance the adverse/toxic effect of Amdinocillin. Specifically, the risk for carnitine deficiency may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Valproate Products may increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Valproate Products may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbapenems: May decrease the serum concentration of Valproate Products. Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproMAZINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cosyntropin: May enhance the hepatotoxic effect of Valproate Products. Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: May decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May increase the serum concentration of Valproate Products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fotemustine: Valproate Products may enhance the adverse/toxic effect of Fotemustine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Valproate Products may enhance the adverse/toxic effect of LamoTRIgine. Valproate Products may increase the serum concentration of LamoTRIgine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: Valproate Products may increase the serum concentration of Lesinurad. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LORazepam: Valproate Products may increase the serum concentration of LORazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Systemic): Valproate Products may increase the serum concentration of Minoxidil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: Valproate Products may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: Valproate Products may decrease the serum concentration of OXcarbazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: Valproate Products may increase the serum concentration of Paliperidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Valproate Products may decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, may be decreased. Primidone may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: Valproate Products may enhance the therapeutic effect of Propofol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Valproate Products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: Valproate Products may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: Valproate Products may increase the serum concentration of Rufinamide.  Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Valproate Products may increase the serum concentration of Sodium Oxybate.  Management: Consider a sodium oxybate dose reduction of at least 20% if combined with valproic acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temozolomide: Valproate Products may enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the adverse/toxic effect of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Valproate Products may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Valproate Products may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorinostat: Valproate Products may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Valproate Products may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233015\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Food may delay but does not affect the extent of absorption. Management: May administer with food if GI upset occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232987\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (migraine prophylaxis)/D (all other indications) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233002\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies and in human pregnancies. <b>[US Boxed Warning]: May cause major congenital malformations, such as neural tube defects (eg, spina bifida) and decreased IQ scores following in utero exposure. Use is contraindicated in pregnant women for the prevention of migraine. Use is not recommended in women of childbearing potential for any other condition unless valproate is essential to manage her condition and alternative therapies are not appropriate. Effective contraception should be used during therapy. </b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Valproic acid crosses the placenta (Harden 2009b). Neural tube defects, craniofacial defects, cardiovascular malformations, hypospadias, and limb malformations have been reported. Information from the North American Antiepileptic Drug Pregnancy Registry notes the rate of major malformations to be 9% to 11% following an average exposure to valproate monotherapy 1,000 mg/day; this is an increase in congenital malformations when compared with monotherapy with other antiepileptic drugs (AED). Based on data from the CDC National Birth Defects Prevention Network, the risk of spinal bifida is approximately 1% to 2% following valproate exposure (general population risk estimated to be 0.06% to 0.07%).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Nonteratogenic adverse effects have also been reported. Decreased IQ scores have been noted in children exposed to valproate in utero when compared to children exposed to other antiepileptic medications or no antiepileptic medications; the risk of autism spectrum disorders may also be increased. Fatal hepatic failure and hypoglycemia in infants have been noted in case reports following in utero exposure to valproic acid.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Clotting factor abnormalities (hypofibrinogenemia, thrombocytopenia, or decrease in other coagulation factors) may develop in the mother following valproate use during pregnancy; close monitoring of coagulation factors is recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines recommend complete avoidance of valproic acid and derivatives for the treatment of epilepsy in pregnant women whenever possible (Harden 2009a), especially when used for conditions not associated with permanent injury or risk of death. Effective contraception should be used during treatment. When pregnancy is being planned, consider tapering off of therapy prior to conception if appropriate; abrupt discontinuation of therapy may cause status epilepticus and lead to maternal and fetal hypoxia. Folic acid decreases the risk of neural tube defects in the general population; supplementation with folic acid should be used prior to conception and during pregnancy in all women, including those taking valproate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry is available for women who have been exposed to valproic acid. Patients may enroll themselves in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055960\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver enzymes (prior to therapy and at frequent intervals, especially during the first 6 months), bilirubin, serum ammonia (with symptoms of lethargy, mental status change), CBC with platelets (prior to initiation and periodically during therapy), serum concentrations, PT/PTT (especially prior to surgery); signs and symptoms of suicidality (eg, anxiety, depression, behavior changes), motor and cognitive function  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055964\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Additional patient-specific factors must be taken into consideration when interpreting drug concentrations, including indication, age, clinical response, pregnancy status, adherence, comorbidities, adverse effects, and concomitant medications (Patsalos 2008; Reed 2006). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Seizure disorder: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Therapeutic: 50 to 100 mcg/mL (SI: 350 to 690 micromoles/L); the relationship between plasma concentration and therapeutic response is not well documented; some patients may require lower concentrations to achieve therapeutic effect, and others may require higher concentration, but have a higher risk of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Toxic: &gt;100 to 150 mcg/mL (SI: &gt;690 to 1040 micromoles/L); probability of thrombocytopenia increases with total valproate concentrations &ge;110 mcg/mL (SI: &ge;760 micromoles/L) in females or &ge;135 mcg/mL (SI: &ge;930 micromoles/L) in males </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Seizure control may improve at concentrations &gt;100 mcg/mL (SI: &gt;690 micromoles/L), but toxicity may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mania: Therapeutic trough: 50 to 125 mcg/mL (SI: 350 to 860 micromoles/L); risk of toxicity increases at concentrations &gt;125 mcg/mL (SI: 875 micromole/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232978\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes increased availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to brain neurons or may enhance the action of GABA or mimic its action at postsynaptic receptor sites. Divalproex sodium is a compound of sodium valproate and valproic acid; divalproex dissociates to valproate in the GI tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232997\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes into CSF at concentrations similar to unbound concentration in plasma (ie, ~10% of total plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: Total valproate: 11 L/1.73 m<sup>2</sup>; Free valproate 92 L/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent): 80% to 90%; free fraction: ~10% at 40 mcg/mL and ~18.5% at 130 mcg/mL; protein binding decreased in neonates, the elderly and patients with hepatic or renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via glucuronide conjugation (30% to 50% of administered dose) and 40% via mitochondrial beta-oxidation; other oxidative metabolic pathways occur to a lesser extent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Depakote ER: ~90% relative to IV dose and ~89% relative to delayed release formulation. In pediatric patients 10 to 17 years of age, once-daily administration of Depakote-ER produced valproate plasma concentration-time profiles similar to adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (increased in neonates, elderly, and patients with liver impairment):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns (exposed to VPA in utero): 30 to 60 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates first week of life: 40 to 45 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &lt;10 days: 10 to 67 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;2 months: 7 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 2 to 14 years: 9 hours (range: 3.5 to 20 hours) (Cloyd 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 9 to 19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Depakote tablet and sprinkle capsules: ~4 hours; Depakote ER: 4 to 17 hours; Stavzor: 2 hours; Epival [Canadian product]: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal (off-label route): 1 to 3 hours (Graves 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (30% to 50% as glucuronide conjugate, &lt;3% as unchanged drug); faster clearance in children who receive other antiepileptic drugs and those who are younger; age and polytherapy explain 80% of interpatient variability in total clearance; children &gt;10 years of age have pharmacokinetic parameters similar to adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> ER tablets have 10% to 20% less fluctuation in serum concentration than delayed-release tablets. ER tablets are not bioequivalent to delayed-release tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570489\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Stavzor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $153.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $301.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $555.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Depakote Sprinkles Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $137.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, sprinkles</b> (Divalproex Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $89.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Depakene Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $404.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Valproic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $82.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Depacon Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $25.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Valproate Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (5 mL): $8.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Depakene Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (480 mL): $413.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Depakote ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $257.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $453.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Divalproex Sodium ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $167.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $295.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Depakote Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $144.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $283.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $522.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Divalproex Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $89.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $176.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $324.97</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233005\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Absenor (SE);</li>\n      <li>Aleptiz (PH);</li>\n      <li>Apilepsin (HR);</li>\n      <li>Convulex (AT, BE, BG, CH, CZ, DE, EE, GB, HN, HU, IE, LU, PL, RU, SG, TR, TW);</li>\n      <li>Delepsine (DK);</li>\n      <li>Depacon (KP, PH);</li>\n      <li>Depakene (AR, CN, CO, ID, JP, PE, PH, PY, UY);</li>\n      <li>Depakin (IT, PK, RU, TR);</li>\n      <li>Depakine (AE, AT, BE, BG, BH, CH, CY, EE, EG, ES, FR, GR, HN, HU, IQ, IR, JO, KW, LB, LU, LY, OM, PL, PT, QA, RU, SA, SY, TH, VE, YE);</li>\n      <li>Depakine Chrono (KP, LU, TH, TW);</li>\n      <li>Depakote (BZ, SR);</li>\n      <li>Deprakine (DK, FI, NO);</li>\n      <li>Desorate (TH);</li>\n      <li>Epilim (AU, BF, BJ, CI, ET, GB, GH, GM, GN, HK, IE, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NZ, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Epilim Chrono 500 (BB, BM, BS, GY, HK, JM, MY, NL, PR, TT);</li>\n      <li>Episenta (GB);</li>\n      <li>Epival (AE, BH, CR, CY, DO, EG, GT, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PH, QA, SA, SV, SY, YE);</li>\n      <li>Ergenyl (SE);</li>\n      <li>Everiden (HU);</li>\n      <li>Lepavent (TW);</li>\n      <li>Leptilan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Neuractin (CO);</li>\n      <li>Oltril (TH);</li>\n      <li>Orfiril (CZ, DE, FI, HU);</li>\n      <li>Orfiril Retard (SG);</li>\n      <li>Petilin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Valcote (CO, EC);</li>\n      <li>Valeptol SR (KP);</li>\n      <li>Valpakine (BR, EC);</li>\n      <li>Valparin (TH);</li>\n      <li>Valporal (IL);</li>\n      <li>Valprax (PE);</li>\n      <li>Valpro (AU, HK);</li>\n      <li>Valpron (VE);</li>\n      <li>Valsup (CO);</li>\n      <li>Valtec-CR (IN);</li>\n      <li>Vematina (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. <i>Headache</i>. 2008, 48(7):1012-1025.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18705027 /pubmed\" target=\"_blank\" id=\"18705027 \">18705027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. <i>Headache</i>. 2009;49(1):45-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19040679 /pubmed\" target=\"_blank\" id=\"19040679 \">19040679 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apostol G, Pakalnis A, Laforet GA, et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. <i>Headache</i>. 2009;49(1):36-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19040678 /pubmed\" target=\"_blank\" id=\"19040678 \">19040678 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium Valproate versus Propranolol in paediatric migraine prophylaxis. <i>Eur J Paediatr Neurol</i>. 2005;9(5):333-338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16120482 /pubmed\" target=\"_blank\" id=\"16120482 \">16120482 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al, &quot;Guidelines for the Evaluation and Management of Status Epilepticus,&quot;<i> Neurocrit Care</i>, 2012, 17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. <i>Headache</i>. 2000;40(8):672-676.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10971664 /pubmed\" target=\"_blank\" id=\"10971664 \">10971664 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloyd JC, Fischer JH, Kriel RL, et al, &ldquo;Valproic Acid Pharmacokinetics in Children. IV. Effects of Age and Antiepileptic Drugs on Protein Binding and Intrinsic Clearance,&rdquo; <i>Clin Pharmacol Ther</i>, 1993, 53(1):22-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8422737 /pubmed\" target=\"_blank\" id=\"8422737 \">8422737 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloyd JC, Kriel RL, Fischer JH, et al, &ldquo;Pharmacokinetics of Valproic Acid in Children: I. Multiple Antiepileptic Drug Therapy,&rdquo; <i>Neurology</i>, 1983, 33(2):185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/6401848/pubmed\" target=\"_blank\" id=\"6401848\">6401848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreifuss FE, Santilli N, Langer DH, et al, &ldquo;Valproic Acid Hepatic Fatalities: A Retrospective Review,&rdquo; <i>Neurology</i>, 1987, 37(3):379-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3102998/pubmed\" target=\"_blank\" id=\"3102998\">3102998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evans D and Levene M, &quot;Neonatal Seizures,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 78(1):70-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/9536846/pubmed\" target=\"_blank\" id=\"9536846\">9536846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freeman JM, Vining EP, Cost S, et al, &ldquo;Does Carnitine Administration Improve the Symptoms Attributed to Anticonvulsant Medications?: A Double-Blinded, Crossover Study,&rdquo; <i>Pediatrics</i>, 1994, 93(6 Pt 1):893-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8190572/pubmed\" target=\"_blank\" id=\"8190572\">8190572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gal P, Oles KS, Gilman JT, et al, &quot;Valproic Acid Efficacy, Toxicity, and Pharmacokinetics in Neonates With Intractable Seizures,&quot; <i>Neurology</i>, 1988, 38(3):467-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3126410/pubmed\" target=\"_blank\" id=\"3126410\">3126410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go CY, Mackay MT, Weiss SK, et al, &quot;Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2012, 78(24):1974-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22689735/pubmed\" target=\"_blank\" id=\"22689735\">22689735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser T, Ben-Menachem E, Bourgeois B, et al, &quot;ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes,&quot; <i>Epilepsia</i>, 2006, 47(7):1094-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16886973/pubmed\" target=\"_blank\" id=\"16886973\">16886973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graves NM and Kriel RL, &quot;Rectal Administration of Antiepileptic Drugs in Children,&quot; <i>Pediatr Neurol</i>, 1987, 3(6):321-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3334021/pubmed\" target=\"_blank\" id=\"3334021\">3334021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: part two.<i> Pediatr Health Care</i>. 2008;22(1):52-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18174091 /pubmed\" target=\"_blank\" id=\"18174091 \">18174091 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagg S and Spigset O, &ldquo;Anticonvulsant Use During Lactation,&rdquo; <i>Drug Saf </i>, 2000, 22(6):425-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10877037/pubmed\" target=\"_blank\" id=\"10877037\">10877037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Meador KJ, Pennell PB, et al, &quot;Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009, 73(2):133-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19398681/pubmed\" target=\"_blank\" id=\"19398681\">19398681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harden CL, Pennell PB, Koppel BS, et al, &quot;Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Vitamin K, Folic Acid, Blood Levels, and Breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society,&quot; <i>Neurology</i>, 2009, 73(2):142-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19398680/pubmed\" target=\"_blank\" id=\"19398680\">19398680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilmas E and Lee CK, &ldquo;Valproic Acid-Related Reye's-Like Syndrome,&rdquo; <i>The Journal of Pediatric Pharmacy Practice</i>, 2000, 5(3):149-55.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.<i> Neurology</i>. 2004;63(12):2215-2224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15623677 /pubmed\" target=\"_blank\" id=\"15623677 \">15623677 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Limdi NA, Knowlton RK, Cofield SS, et al, &quot;Safety of Rapid Intravenous Loading of Valproate,&quot; <i>Epilepsia</i>, 2007, 48(3):478-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17319914/pubmed\" target=\"_blank\" id=\"17319914\">17319914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Limdi NA, Shimpi AV, Faught E, et al, &quot;Efficacy of Rapid IV Administration of Valproic Acid for Status Epilepticus,&quot; <i>Neurology</i>, 2005, 64(2):353-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15668440/pubmed\" target=\"_blank\" id=\"15668440\">15668440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehta V, Singhi P, and Singhi S, &quot;Intravenous Sodium Valproate Versus Diazepam Infusion for the Control of Refractory Status Epilepticus in Children: A Randomized Controlled Trial,&quot; <i>J Child Neurol</i>, 2007, 22(10):1191-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17940245/pubmed\" target=\"_blank\" id=\"17940245\">17940245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meierkord H, Boon P, Engelsen B, et al, &quot;EFNS Guideline on the Management of Status Epilepticus,&quot; <i>Eur J Neurol</i>, 2006, 13(5):445-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16722966/pubmed\" target=\"_blank\" id=\"16722966\">16722966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy JV, Groover RV and Hodge C, &ldquo;Hepatotoxic Effects in a Child Receiving Valproate and Carnitine,&rdquo; <i>J Pediatr</i>, 1993, 123(2):318-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8345435 /pubmed\" target=\"_blank\" id=\"8345435 \">8345435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patsalos PN, Berry DJ, Bourgeois BF, et al, &ldquo;Antiepileptic Drugs -- Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies,&rdquo; <i>Epilepsia</i>, 2008, 49(7):1239-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18397299/pubmed\" target=\"_blank\" id=\"18397299\">18397299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pi&ntilde;a-Garza JE. <i>Fenichel's Clinical Pediatric Neurology: A Signs and Symptoms Approach.</i> 7th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramsay RE, Cantrell D, Collins SD, et al, &quot;Safety and Tolerance of Rapidly Infused Depacon. A Randomized Trial in Subjects With Epilepsy,&quot; <i>Epilepsy Res</i>, 2003, 52(3):189-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12536052/pubmed\" target=\"_blank\" id=\"12536052\">12536052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raskind JY and El-Chaar GM, &quot;The Role of Carnitine Supplementation During Valproic Acid Therapy,&quot; <i>Ann Pharmacother</i>, 2000, 34(5):630-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10852092/pubmed\" target=\"_blank\" id=\"10852092\">10852092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed RC and Dutta S, &ldquo;Does It Really Matter When a Blood Sample for Valproic Acid Concentration Is Taken Following Once-Daily Administration of Divalproex-ER?&rdquo; <i>Ther Drug Monit</i>, 2006, 28(3):413-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16778728/pubmed\" target=\"_blank\" id=\"16778728\">16778728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. <i>Headache</i>. 2002;42(8):819-822.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12390647 /pubmed\" target=\"_blank\" id=\"12390647 \">12390647 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snead OC 3rd and Miles MV, &quot;Treatment of Status Epilepticus in Children With Rectal Sodium Valproate,&quot; <i>J Pediatr</i>, 1985, 106(2):323-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3918159/pubmed\" target=\"_blank\" id=\"3918159\">3918159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uberall MA, Trollmann R, Wunsiedler U, et al, &quot;Intravenous Valproate in Pediatric Epilepsy Patients With Refractory Status Epilepticus,&quot; <i>Neurology</i>, 2000, 54(11):2188-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10851397/pubmed\" target=\"_blank\" id=\"10851397\">10851397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yu KT, Mills S, Thompson N, et al, &quot;Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures,&quot; <i>Epilepsia</i>, 2003, 44(5):724-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12752474/pubmed\" target=\"_blank\" id=\"12752474\">12752474</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12873 Version 235.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708868\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F233020\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233021\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055961\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445214\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055952\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232991\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F232975\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22782778\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49367104\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F16335927\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055966\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133423\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F233013\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055965\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F233076\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233074\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232998\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232979\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819284\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F233062\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15578418\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F233015\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232987\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233002\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055960\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1055964\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232978\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F232997\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570489\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233005\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12873|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">Valproate: Drug information</a></li><li><a href=\"topic.htm?path=valproate-patient-drug-information\" class=\"drug drug_patient\">Valproate: Patient drug information</a></li></ul></div></div>","javascript":null}